PL2682120T3 - Stabilne preparaty lakwinimodu - Google Patents
Stabilne preparaty lakwinimoduInfo
- Publication number
- PL2682120T3 PL2682120T3 PL13187258T PL13187258T PL2682120T3 PL 2682120 T3 PL2682120 T3 PL 2682120T3 PL 13187258 T PL13187258 T PL 13187258T PL 13187258 T PL13187258 T PL 13187258T PL 2682120 T3 PL2682120 T3 PL 2682120T3
- Authority
- PL
- Poland
- Prior art keywords
- preparations
- stable
- stable laquinimod
- laquinimod preparations
- laquinimod
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B25/00—Packaging other articles presenting special problems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US869807P | 2007-12-20 | 2007-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2682120T3 true PL2682120T3 (pl) | 2017-02-28 |
Family
ID=40788935
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13187258T PL2682120T3 (pl) | 2007-12-20 | 2008-12-19 | Stabilne preparaty lakwinimodu |
PL08864658T PL2234485T3 (pl) | 2007-12-20 | 2008-12-19 | Stabilne preparaty lakwinimodu |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08864658T PL2234485T3 (pl) | 2007-12-20 | 2008-12-19 | Stabilne preparaty lakwinimodu |
Country Status (12)
Country | Link |
---|---|
US (3) | US8178127B2 (pl) |
EP (3) | EP2977049A1 (pl) |
DK (1) | DK2234485T3 (pl) |
ES (2) | ES2600920T3 (pl) |
HK (1) | HK1220126A1 (pl) |
HR (1) | HRP20140138T1 (pl) |
IL (1) | IL205855A (pl) |
PL (2) | PL2682120T3 (pl) |
PT (2) | PT2682120T (pl) |
RS (1) | RS53199B (pl) |
SI (1) | SI2234485T1 (pl) |
WO (1) | WO2009082471A1 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
ES2377149T3 (es) | 2006-06-12 | 2012-03-22 | Teva Pharmaceutical Industries Limited | Preparaciones de laquinimod estables |
EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
RS54328B1 (en) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS |
PL2458992T3 (pl) * | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
SI2467372T1 (sl) * | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda |
CN102781239B (zh) * | 2010-03-03 | 2015-01-21 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮关节炎 |
DK2542079T3 (da) * | 2010-03-03 | 2014-08-25 | Teva Pharma | Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat |
KR20160129093A (ko) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
EA201390074A1 (ru) * | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения |
JP2013535437A (ja) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたn−エチル−n−フェニル−1,2−ジヒドロ−4−ヒドロキシ−5−クロロ−1−メチル−2−オキソキノリン−3−カルボキサミド、その塩および使用 |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
MX2014009889A (es) * | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
AU2013341506A1 (en) | 2012-11-07 | 2015-06-04 | Teva Pharmaceutical Industries Ltd. | Amine salts of Laquinimod |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
EP2968203A1 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
CN106573014A (zh) | 2014-04-29 | 2017-04-19 | 梯瓦制药工业有限公司 | 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
WO2022127827A1 (zh) * | 2020-12-17 | 2022-06-23 | 上海维申医药有限公司 | Kras g12c蛋白突变抑制剂、其制备方法、药物组合物及其应用 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3024257A (en) * | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
DE3437232A1 (de) * | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
US5912349A (en) * | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
CA2376202C (en) | 1999-06-07 | 2008-11-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel preparation and administration form comprising an acid-labile active compound |
CN100390148C (zh) * | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
US6802422B2 (en) * | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
US6706733B2 (en) * | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
MXPA05008491A (es) | 2003-02-20 | 2006-02-22 | Bpsi Holdings Inc | Sistemas de recubrimiento de pelicula nacarada y substratos recubiertos con la misma. |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US20060188568A1 (en) | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US20070163917A1 (en) | 2004-07-16 | 2007-07-19 | Pfizer Inc. | Package and device for simultaneously maintaining low moisture and low oxygen levels |
US8562493B2 (en) | 2005-02-11 | 2013-10-22 | Joseph Haven (Haviv) | Exercise and training apparatus |
KR101440982B1 (ko) * | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
ES2377149T3 (es) | 2006-06-12 | 2012-03-22 | Teva Pharmaceutical Industries Limited | Preparaciones de laquinimod estables |
EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
RS54328B1 (en) | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS |
PL2458992T3 (pl) | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
SI2467372T1 (sl) | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda |
DK2542079T3 (da) | 2010-03-03 | 2014-08-25 | Teva Pharma | Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat |
CN102781239B (zh) | 2010-03-03 | 2015-01-21 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮关节炎 |
KR20160129093A (ko) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
JP2013535437A (ja) | 2010-07-09 | 2013-09-12 | テバ ファーマシューティカル インダストリーズ リミティド | 重水素化されたn−エチル−n−フェニル−1,2−ジヒドロ−4−ヒドロキシ−5−クロロ−1−メチル−2−オキソキノリン−3−カルボキサミド、その塩および使用 |
EA201390074A1 (ru) | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения |
EA201390827A1 (ru) | 2010-12-07 | 2013-12-30 | Тева Фармасьютикал Индастриз Лтд. | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом |
IN2014MN00333A (pl) | 2011-07-28 | 2015-09-25 | Teva Pharma | |
JP2014521659A (ja) | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
-
2008
- 2008-12-19 EP EP15181302.9A patent/EP2977049A1/en not_active Withdrawn
- 2008-12-19 WO PCT/US2008/013890 patent/WO2009082471A1/en active Application Filing
- 2008-12-19 ES ES13187258.2T patent/ES2600920T3/es active Active
- 2008-12-19 PT PT131872582T patent/PT2682120T/pt unknown
- 2008-12-19 EP EP13187258.2A patent/EP2682120B1/en active Active
- 2008-12-19 ES ES08864658T patent/ES2445451T3/es active Active
- 2008-12-19 RS RSP20140072 patent/RS53199B/en unknown
- 2008-12-19 PL PL13187258T patent/PL2682120T3/pl unknown
- 2008-12-19 PT PT08864658T patent/PT2234485E/pt unknown
- 2008-12-19 PL PL08864658T patent/PL2234485T3/pl unknown
- 2008-12-19 DK DK08864658T patent/DK2234485T3/da active
- 2008-12-19 EP EP20080864658 patent/EP2234485B1/en active Active
- 2008-12-19 US US12/317,104 patent/US8178127B2/en active Active
- 2008-12-19 SI SI200831146T patent/SI2234485T1/sl unknown
-
2010
- 2010-05-20 IL IL205855A patent/IL205855A/en not_active IP Right Cessation
-
2012
- 2012-05-14 US US13/471,175 patent/US8545885B2/en not_active Expired - Fee Related
-
2013
- 2013-09-20 US US14/032,425 patent/US9340307B2/en active Active
-
2014
- 2014-02-13 HR HRP20140138AT patent/HRP20140138T1/hr unknown
-
2016
- 2016-07-13 HK HK16108224.3A patent/HK1220126A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2234485A1 (en) | 2010-10-06 |
US20140024678A1 (en) | 2014-01-23 |
EP2977049A1 (en) | 2016-01-27 |
SI2234485T1 (sl) | 2014-03-31 |
RS53199B (en) | 2014-06-30 |
PT2682120T (pt) | 2016-11-07 |
ES2600920T3 (es) | 2017-02-13 |
US9340307B2 (en) | 2016-05-17 |
IL205855A (en) | 2017-02-28 |
US20090162432A1 (en) | 2009-06-25 |
WO2009082471A1 (en) | 2009-07-02 |
DK2234485T3 (da) | 2014-02-10 |
US8545885B2 (en) | 2013-10-01 |
HRP20140138T1 (hr) | 2014-04-11 |
EP2682120B1 (en) | 2016-08-03 |
HK1220126A1 (zh) | 2017-04-28 |
PT2234485E (pt) | 2014-02-17 |
US8178127B2 (en) | 2012-05-15 |
EP2234485A4 (en) | 2011-02-16 |
EP2682120A1 (en) | 2014-01-08 |
IL205855A0 (en) | 2010-11-30 |
US20120225124A1 (en) | 2012-09-06 |
EP2234485B1 (en) | 2013-11-13 |
ES2445451T3 (es) | 2014-03-03 |
PL2234485T3 (pl) | 2014-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1220126A1 (zh) | 穩定的拉喹莫德製劑 | |
IL195724A0 (en) | Stable laquinimod preparations | |
EP2225275A4 (en) | PROTEIN FORMULATION | |
HK1149756A1 (en) | Isoxazolo-pyridine derivatives | |
EP2120569A4 (en) | SPIROCHROMANONDERIVATE | |
IL193265A0 (en) | Quinoline derivatives | |
IL202020A0 (en) | Spiroindolinone derivatives | |
GB0711656D0 (en) | Formulations | |
GB0716385D0 (en) | Formulations | |
IL200618A0 (en) | Aza-pyridopyrimidinone derivatives | |
GB0712884D0 (en) | Formulations | |
GB0711957D0 (en) | Formulations | |
GB0809979D0 (en) | Formulations | |
EP2133347A4 (en) | 1-BIARYLAZETIDINONDERIVATE | |
GB0810232D0 (en) | Formulations | |
HK1141009A1 (en) | Sulfonyl-quinoline derivatives | |
IL202159A0 (en) | Piperidine-amide derivatives | |
GB0718346D0 (en) | Tooth-bleaching preparations | |
HK1146276A1 (en) | Thiadiazinone derivatives | |
EP2204368A4 (en) | 4-SULFONYLPIPERIDINE DERIVATIVES | |
GB0705179D0 (en) | Formulations | |
ZA200806877B (en) | Quinoline Derivatives | |
AU4913P (en) | KencoralGL Kennedia coccinea | |
GB0706970D0 (en) | Fermented ingredient | |
PL381845A1 (pl) | Preparat bitumujący |